

2018 Public Outcomes Report
Commission on Cancer
Cancer Program Practice Profile Reports

As Commission on Cancer (CoC)-accredited cancer programs, HealthEast, Fairview Southdale and Fairview Ridges ensure that patients with cancer are treated according to nationally accepted measures.

Measures for Quality of Cancer Care

Each year, CoC-accredited programs are required to review their quality of patient care using the Cancer Program Practice Profile Reports (CP³R).

The CP³R analyzes performance compared to the national standard of care for selected cancer sites. The CP³R also provides aggregate feedback for comparison with similar CoC-accredited cancer programs.

The CoC partners with internal and external clinical experts to develop quality measures. The Fairview and HealthEast cancer registries collect the necessary data to assess and monitor concordance with the measures. The results are reported to the National Cancer Data Base (NCDB), a joint program of the American College of Surgeons (ACoS) and the American Cancer Society (ACS). NCDB is a clinical oncology outcomes database for more than 1,500 commission-accredited cancer programs.

This report focuses on quality measures for breast and colon cancer. The report includes patients diagnosed in 2016.

Commission on Cancer Overview

The Commission on Cancer (CoC), a program of the American College of Surgeons (ACoS), recognizes cancer care programs for their commitment to providing comprehensive, high-quality, and multidisciplinary patient centered care.

The CoC accreditation program is voluntary and encourages hospitals to improve quality of patient care through various cancer-related programs. These programs address the full continuum of cancer from prevention through hospice and end-of-life care, or survivorship and quality of life.

Our Cancer programs recognize the value of accreditation and have long partnered with the Commission on Cancer, maintaining accreditation at HealthEast since 1987, Fairview Southdale since 2006 and Fairview Ridges since 2008.

**2018 Public Outcomes Report
Commission on Cancer
Cancer Program Practice Profile Reports**

BREAST AND COLON CANCER DIAGNOSIS YEAR: 2016	Estimated Performance Rates					
	HealthEast	Fairview Southdale	Fairview Ridges	Minnesota	All CoC Approved-Programs	National Benchmark*
Breast Cancer						
Radiation therapy is administered within one year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.	94.4%	100%	92.0%	93.9%	91.6%	90%
Tamoxifen or third generation aromatase inhibitor is recommended or administered within one year (365 days) of diagnosis for women with AJCC T1cN0M0, or Stage IB – III hormone receptor positive breast cancer.	97.7%	98.9%	94.6%	96.8%	92.6%	90%
Radiation Therapy is recommended or administered following any mastectomy within one year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive lymph nodes.	100%	100%	100%	95.9%	87.6%	90%
Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer.	97.6%	98.4%	85.7%	95.0%	91.6%	80%
Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer.	77.5%	69.2%	67.6%	66.2%	67.4%	Not applicable
Colon Cancer						
At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.	91.3%	75.9%	100%	92.4%	92.8%	85%
Adjuvant chemotherapy is recommended, or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC stage III (lymph node positive) colon cancer.	100%	100%	100%	95.5%	88.6%	Not applicable

*Expected performance rates for Commission-approved programs